Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of subcutaneous abatacept in CTLA4 insufficiency or LRBA deficiency
DRKS00017736Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in CTLA4 deficiency, LRBA deficiency (LRBA) and immunocompromise, sponsored by Universitätsklinikum Freiburg. Started Jul 2020; status: completed.
02
Drugs
abatacept
03
Conditions
CTLA4 deficiencyLRBA deficiency (LRBA)immunocompromise
Beyond the preview
Go deeper on DRKS00017736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00017736.